Biology of disease-related molecules

1. Production of beta-amyloid

- Carmela R. Abraham, Ph.D.
  Boston University Medical Campus
  Boston, Massachusetts
  **Modulators of APP Dimerization as Novel Therapeutics for Alzheimer’s Disease**
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  Does dimerization of APP affect the production of beta-amyloid, and could this be a useful target for drugs to halt or slow the progression of Alzheimer’s disease?

- Alessia Barbagallo, Ph.D.
  Albert Einstein College of Medicine at Yeshiva University
  Bronx, New York
  **The Role of APP Phosphorylation Induced by IGF-1 in APP Processing**
  2010 New Investigator Research Grant—$80,000 over 2 years
  How do abnormal phosphorylation and the loss of normal IGF-1 activity affect APP processing in cells and lead to brain cell damage?

- Giuseppe Di Fede, M.D., Ph.D.
  Fondazione IRCCS Istituto Neurologico Carlo Besta Milan, Italy
  **Trans-suppression of Abeta Amyloidogenesis in Cellular and Nematode Models**
  2010 New Investigator Research Grant—$50,000 over 2 years
  What biological mechanisms underlie an APP variant’s ability to promote harmful amyloid clumping?

- Joseph D. Fondell, Ph.D.
  University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School
  Piscataway, New Jersey
  **T3-Dependent Silencing of Beta-Amyloid Precursor Protein Gene Expression**
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How does T3 regulate the expression of APP and what other proteins assist in this process?

- Laura Beth McIntire, Ph.D.
  Columbia University Medical Center
  New York, New York
  **Dissecting the Role of PI3K Family Members in Aβ Biogenesis**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Is the protein ataxia telangiectasia mutated kinase (ATM) or another kinase most responsible for regulating beta-amyloid production?

- Amantha Thathiah, Ph.D.
  VIBvzw
  Leuven, Belgium
  **Regulation of the Gamma-Secretase and Abeta Peptide Generation by GPR3**
  2010 Mentored New Investigator Research Grant to Promote Diversity—$150,000 over 3 years
  Does the removal of the GPR3 gene in mice inhibit the formation of amyloid plaque?

- Yunwu Zhang, Ph.D.
  Xiamen University
  Xiamen, China
  **The Involvement of CutA in Alzheimer’s Disease**
  2010 New Investigator Research Grant—$80,000 over 2 years
  What are the roles of CutA and copper atoms in the regulation of BACE1 and the production of beta-amyloid?

2. Tau phosphorylation

- Kanae Iijima-Ando, Ph.D.
  Thomas Jefferson University
  Philadelphia, Pennsylvania
  **Tau Phosphorylation and Toxicity Induced by Mitochondrial Mislocalization**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does abnormal mitochondrial transport promote tau toxicity in cells by enhancing tau phosphorylation in certain disease-affected brain regions?

- Umesh Kumar Jinwal, Ph.D.
  University of South Florida
  Tampa, Florida
  **Behavioral and Biochemical Analysis of Mice Lacking FKB51**
  2010 New Investigator Research Grant—$50,000 over 2 years
  Does eliminating FKB51 in healthy mice alter the production of normal tau and lead to behavioral changes?

- Nicholas M. Kanaan, Ph.D.
  Northwestern University—Chicago Campus
  Chicago, Illinois
  **Tau-Mediated Axonal Transport Dysfunction**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does the phosphatase-activating domain (PAD) hinder axonal transport through a process that phosphorylates tau?

- Fei Liu, Ph.D.
  Research Foundation for Mental Hygiene, Inc. at New York State Institute for Basic Research
  New York, New York
  **Role of Dyrk1A in Tau Pathology in Alzheimer’s Disease**
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How does modification of Dyrk1A during the disease process affect the phosphorylation of tau, as well as the expression of different forms of tau?

- Fengquan Zhou, Ph.D.
  Johns Hopkins University School of Medicine
  Baltimore, Maryland
  **Regulation of Tau Phosphorylation in Neurons by Par3/6 via GSK-3s**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Is Par3/6 activity part of a signaling pathway activated by known signals, such as growth factors?
3. Normal function of disease-related proteins

- **Christopher Conrad, Ph.D.**
  Columbia University
  New York, New York
  *The Role of SorLA in Tau Aggregation*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does decreased sorLA expression lead to the overproduction of abnormal tau protein and the development of neurofibrillary tangles?

- **Sebastien Gauthier, Ph.D.**
  The Nathan S. Kline Institute for Psychiatric Research
  Orangeburg, New York
  *CysC Restores the Flow of Autophagy to Counteract Alzheimer Pathogenesis*
  2010 New Investigator Research Grant—$80,000 over 2 years
  How and where do Alzheimer-related proteins accumulate in cells?

- **Ulrich Hengst, Ph.D.**
  Columbia University Medical Center
  New York, New York
  *The Role of Intra-Axonal Protein Synthesis in Alzheimer’s Disease*
  2010 New Investigator Research Grant—$80,000 over 2 years
  How and where do Alzheimer-related proteins accumulate in cells?

- **Nikolaos K. Robakis, Ph.D.**
  Mount Sinai School of Medicine
  New York, New York
  *Neuroprotective Functions of Progranulin and Receptor*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How do mutations in progranulin lead to neurodegeneration?

- **Jie Shen, Ph.D.**
  Brigham and Women’s Hospital
  Boston, Massachusetts
  *Role of APP Family in the Synapse*
  2010 Zenith Fellows Award—$450,000 over 3 years
  What are the functions of APP in brain cells and synapses?

- **Marcel M. Verbeek, Ph.D.**
  Radboud University Nijmegen Medical Centre
  Nijmegen, Netherlands
  *ApoE and ApoJ in the Cerebrovascular Clearance of Amyloid Beta Protein*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How does amyloid beta interact with ApoE and ApoJ, and how is this interaction important for removal of beta-amyloid from the brain?

- **Huaxi Xu, Ph.D.**
  Burnham Institute for Medical Research
  La Jolla, California
  *Appoptosin, an APP Binding Proapoptotic Protein, Mediates Neuronal Death*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How does appoptosin trigger cell death, and how is that process influenced by binding of APP?

---

**Alzheimer’s disease pathology**

1. Properties and toxicity of abnormal protein structures

- **Natália Carulla, Ph.D.**
  Institute for Research in Biomedicine, Barcelona
  Barcelona, Spain
  *Structure-Toxicity Relationship of Abeta Oligomers*
  2010 New Investigator Research Grant—$80,000 over 2 years
  What is the exact structure of the most toxic amyloid oligomers?

- **Claudio Hetz, Ph.D.**
  Institute of Biomedical Sciences, University of Chile
  Santiago, Chile
  *Defining the Role of the Unfolded Protein Response in Alzheimer’s Disease*
  2010 New Investigator Research Grant—$80,000 over 2 years
  How does x-box binding protein-1 (XBP-1) make brain cells vulnerable to amyloid-induced damage?

- **Keith A. Johnson, M.D.**
  Massachusetts General Hospital
  Boston, Massachusetts
  *Tracking the Progression of Early Amyloid Deposition*
  2010 Zenith Fellows Award—$449,214 over 3 years
  What are the patterns of amyloid plaque formation and the rate of plaque formation, and which features of amyloid plaque are associated with brain degeneration?

- **Efrat Levy, Ph.D.**
  The Nathan S. Kline Institute for Psychiatric Research
  Orangeburg, New York
  *Transgenic Models of the Anti-Amyloidogenic Activity of a Mutant Form of Abeta*
  2010 Zenith Fellows Award—$450,000 over 3 years
  How does mutant APP affect the aggregation of beta-amyloid and the development of amyloid plaque?

- **Anant Krishna Paravastu, Ph.D.**
  Florida State University Research Foundation, Inc.
  Tallahassee, Florida
  *NMR Characterization of Prefibrillar Amyloid-Beta Aggregates*
  2010 New Investigator Research Grant—$80,000 over 2 years
  What is the exact structure of early oligomer formations?

- **Jonathan Pierce-Shimomura, Ph.D.**
  University of Texas at Austin
  Austin, Texas
  *Mechanisms of APP-Induced Death of Cholinergic Neurons in C. Elegans*
  2010 New Investigator Research Grant—$80,000 over 2 years
  How does APP overexpression damage roundworm cholinergic neurons?

2. Mediators of beta-amyloid toxicity

- **Nelson Arispe, Ph.D.**
  The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
  Rockville, Maryland
  *Contribution of Alzheimer Abeta Channels to the Abeta-Induced Calcium Response*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  Are channels formed by beta-amyloid in the cell membrane responsible for the toxicity of beta-amyloid in nerve cells?
• Rodrigo Franco, Ph.D.
  University of Nebraska
  Lincoln, Nebraska
  
  **Copper Transport Regulates Amyloid-Beta-Induced Neurodegeneration**
  2010 New Investigator Research Grant to Promote Diversity—$99,624 over 2 years
  What is the role of the proteins ATP7a and CTR1 in the regulation of copper levels in the brain and within nerve cells of the brain?

• Mi Hee Lim, Ph.D.
  University of Michigan
  Ann Arbor, Michigan
  
  **The Roles of Metal Ions in Alzheimer's Disease**
  2010 New Investigator Research Grant—$79,999 over 2 years
  Do metal ions promote beta-amyloid accumulation by reducing the activity of enzymes that clear amyloid from the brain?

• Izumi Maezawa, Ph.D.
  University of California, Davis
  Davis, California
  
  **The Role of the Potassium Channel Kv1.3 in Aβ-Induced Microglia Activation**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does blocking the Kv1.3 channel prevent microglia from causing inflammation without hindering the cells' ability to clear beta-amyloid?

• Ewan C. McNay, Ph.D.
  University at Albany - SUNY
  Albany, New York
  
  **Diabetes, Insulin, Amyloid and Alzheimer's Disease: Cognitive and Metabolic Mechanisms**
  2010 New Investigator Research Grant—$80,000 over 2 years
  How do brain cells use different proteins to communicate with one another in Alzheimer’s?

• Salvatore Oddo, Ph.D.
  University of Texas Health Science Center
  San Antonio, Texas
  
  **The Role of Chaperone-Mediated Autophagy in Alzheimer's Disease**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does amyloid accumulation in the brain impair chaperone-mediated autophagy (CMA) activity and lead to the build-up of tau and further build-up of beta-amyloid?

• Zhigang Xiong, Ph.D.
  Legacy Emanuel Hospital and Health Center
  Portland, Oregon
  
  **Acid-Sensing Ion Channels as Novel Target for Alzheimer's Disease**
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How does beta-amyloid affect the activity of acid-sensing ion channels?

3. **Synaptic dysfunction**

• Ayodeji Abdur-Rasheed Asuni, Ph.D.
  New York University School of Medicine
  New York, New York
  
  **Astrocytes and Synaptopathy: Protein Misfolding Disease’s Mechanisms**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Do deposits of misfolded beta-amyloid or prion protein lead to synaptic damage and astrocytic buildup in mice?

• Heng Du, M.D., Ph.D.
  Columbia University Medical Center
  New York, New York
  
  **Mitochondrial Permeability Transition Pore and Abeta-Induced Synapse Loss**
  2010 New Investigator Research Grant—$80,000 over 2 years
  How do mitochondrial pores lead to synaptic damage?

• Nicola Origlia, Ph.D.
  Institute of Neuroscience of the National Research Council
  University of Pisa
  Pisa, Italy
  
  **Role of Microglial and Neuronal RAGE in Abeta Mediated Synaptic Dysfunction**
  2010 New Investigator Research Grant—$80,000 over 2 years
  How do amyloid oligomers inhibit the function of synapses, and how does the receptor for advanced glycation endproducts (RAGE) promote amyloid-induced synaptic damage?

4. **Disruption of brain cell functions/properties**

• Andrea Bibbig, Ph.D.
  Research Foundation, SUNY
  Brooklyn, New York
  
  **Deficits of Neuronal Oscillations and Cognition in Alzheimer’s Disease**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does modifying the activity of glutamate and serotonin restore beta and gamma oscillations?

• Donna Cross, Ph.D.
  University of Washington
  Seattle, Washington
  
  **In Vivo Imaging of Axonal Transport Deficits in Alzheimer's Disease**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does GSK-3 hinder axonal transport?

• Elvira De Leonibus, Ph.D.
  Fondazione Telethon
  Rome, Italy
  
  **Neurobiology of Working Memory Span in Normal and Pathological Aging**
  2010 New Investigator Research Grant—$79,970 over 2 years
  What associations exist between working memory loss, aging and AMPA receptor activity?

• Tomas Luis Falzone, Ph.D.
  Institute for Cell Biology and Neuroscience
  Buenos Aires, Argentina
  
  **New Models to Study the Role of Ubiquitin-Proteasome Axonal Transport in Alzheimer’s Disease**
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does axonal damage hinder the transportation of ubiquitin to sites where beta-amyloid and tau accumulate?

• Rong Fan, Ph.D.
  Yale University
  New Haven, Connecticut
  
  **Assessing Heterogeneity of Alzheimer's Disease Using Integrated Microchips**
  2010 New Investigator Research Grant—$80,000 over 2 years
  How do brain cells use different proteins to communicate with one another in Alzheimer’s?
• George Perry, Ph.D.
  Case Western Reserve University
  Cleveland, OH  
  *The Role of PGC-1alpha in Alzheimer’s Disease*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  What causes decreased expression of PGC-1alpha in Alzheimer’s?

• Inna Slutsky, Ph.D.
  Tel-Aviv University
  Tel-Aviv, Israel  
  *Initiation of Alzheimer’s Disease: From Amyloid-Beta Release to Synaptic Failure*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Do altered brain cell activity patterns lead to harmful beta-amyloid release and synaptic damage?

• Xiongwei Zhu, Ph.D.
  Case Western Reserve University
  Cleveland, Ohio  
  *In Vivo Study on Abnormal Mitochondrial Dynamics in Alzheimer Model*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  What molecular mechanisms cause changes in mitochondria during the development of Alzheimer pathology?

• Corinne Engelman, Ph.D.
  University of Wisconsin-Madison
  Madison, Wisconsin  
  *Genetic Architecture of Alzheimer-Related Functional and Structural Brain Aging*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Which SNPs are associated with Alzheimer-related cognitive decline, and which SNPs are linked to structural brain loss?

• Kinga Szigeti, M.D., Ph.D.
  Baylor College of Medicine
  Houston, Texas  
  *Copy Number Variation GWA with Age at Onset of Alzheimer’s Disease*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Which copy number variants are associated with Alzheimer-related cognitive decline, and which SNPs are linked to structural brain loss?

6. Other factors in Alzheimer pathology

• Cheng-Xin Gong, M.D.
  Research Foundation for Mental Hygiene, Inc. at New York State Institute for Basic Research
  New York, New York  
  *Targeting Insulin Signaling for Treating Neurofibrillary Degeneration in Alzheimer’s Disease*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How does loss of insulin signaling contribute to the development of neurofibrillary tangles?

• Henrieta Scholtzova, M.D., Ph.D.
  New York University School of Medicine
  New York, New York  
  *Mechanisms of Action of Innate Immunity Stimulation with CpG ODN on CAA*
  2010 New Investigator Research Grant—$80,000 over 2 years
  How does the activation of macrophages by CpG ODN safely regulate vascular and brain beta-amyloid levels?

• Nicholas H. Varvel, Ph.D.
  Hertie-Institute for Clinical Brain Research
  Tuebingen, Germany  
  *Alzheimer Pathologies in the Absence of Microglia*
  2010 New Investigator Research Grant—$80,000 over 2 years
  What is the role of microglia in the development and maintenance of Alzheimer pathology?

• Riqiang Yan, Ph.D.
  Cleveland Clinic Foundation
  Cleveland, Ohio  
  *Blocking RTN3 Aggregation for Improving Cognitive Function*
  2010 Novel Pharmacological Strategies to Prevent Alzheimer’s Disease—$320,000 over 3 years
  What is the role of RTN3 in the progression of Alzheimer pathology?

**Dementia risk factors**

• Maria M. Corrada, Sc.D.
  University of California, Irvine
  Irvine, California  
  *Vascular Disease in Relation to Dementing Pathologies in the Oldest Old*
  2010 New Investigator Research Grant—$77,422 over 2 years
  How does the dementia risk presented by vascular disorders change in the oldest old?

• Edo Richard, M.D.
  Academic Medical Center
  Amsterdam, the Netherlands  
  *A New Perspective on Dementia: From Vascular Risk Factors to Prevention*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Which cardiovascular factors have the greatest impact on dementia risk, and which types of people would benefit most from reducing dementia risk through cardiovascular treatment?

• Christopher Rowe, M.D., Ph.D.
  CSIRO Preventative Health
  Heidelberg, Australia  
  *AIBL II*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How do diet and lifestyle affect an individual’s risk of developing Alzheimer’s disease?

• Liqin Zhao, Ph.D.
  University of Southern California
  Los Angeles, California  
  *IDE, ER Subtype ApoE Genotype and Alzheimer Prevention Versus Treatment*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How does estrogen regulate levels of IDE in the brain, and how does this regulation influence the risk of Alzheimer pathology?

**Diagnosis and disease monitoring**

1. Biomarkers

• Miia Kivipelto, M.D., Ph.D.
  University of Kuopio
  Kuopio, Finland  
  *Effect of Preventive Interventions on Biomarkers for Cognitive Decline*
  2010 The Senator Mark Hatfield Award for Clinical Research—$200,000 over 3 years
  Which potential biomarkers accurately reflect cognitive decline?
1. **Brain imaging**

- **Adam M. Brickman, Ph.D.**
  Columbia University Medical Center
  New York, New York
  *An Ex-Vivo MRI Study of White Matter Hyperintensities in Aging and Alzheimer’s Disease*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Do people with Alzheimer’s have greater white matter hyperintensity (WMH) concentrations in their parietal regions, and are there any associations between WMH levels and various hallmarks of Alzheimer’s?

2. **Other risk factors**

- **Michael Paul Murphy, Ph.D.**
  University of Kentucky Research Foundation
  Lexington, Kentucky
  *Leptin Resistance and Alzheimer’s Disease*
  2010 New Investigator Research Grant—$200,000 over 3 years
  Is there a possible link between an increased risk of Alzheimer’s disease and the presence of obesity or type 2 diabetes?

**Drug development and clinical interventions**

1. **Drug therapies**

- **Ved Chauhan, Ph.D.**
  Research Foundation for Mental Hygiene, Inc., at New York State Institute for Basic Research
  New York, New York
  *Gelsolin, Trichostatin A and Alzheimer’s Disease*
  2010 Investigator-Initiated Research Grant—$199,218 over 2 years
  Is trichostatin A (TSA) an effective treatment to prevent Alzheimer-like pathology in Alzheimer-like mice?

- **Pankaj Karande, Ph.D.**
  Rensselaer Polytechnic Institute
  Troy, New York
  *Study of Tight Junction Binding Peptides for Drug Delivery Across the BBB*
  2010 New Investigator Research Grant—$79,993 over 2 years
  Can several peptides that bind to claudin 5 penetrate a model blood-brain barrier (BBB) engineered from different human cells?

- **Suzanne Craft, Ph.D.**
  Seattle Institute for Biomedical and Clinical Research
  Seattle, Washington
  *Intranasal Insulin Analogue Effects on CSF and Imaging Biomarkers in MCI*
  2010 Zenith Fellows Award—$449,966 over 2 years
  How does long-acting insulin affect cognitive function, brain blood flow and the levels of chemicals in the CSF known to be associated with MCI?

- **Mark Edward Wheeler, Ph.D.**
  University of Pittsburgh
  Pittsburgh, Pennsylvania
  *Neural Mechanisms of Perceptual Memory Decisions in MCI*
  2010 New Investigator Research Grant—$80,000 over 2 years
  How can fMRI show how the brain perceives, processes and remembers sensory information, and how these brain abilities are altered in persons with MCI?

- **Guofan Xu, Ph.D.**
  University of Wisconsin-Madison
  Madison, Wisconsin
  *Detecting the Cerebral Vascular Function Deficits Associated with Alzheimer’s Disease*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Can MRI detect early stages of Alzheimer’s disease using measurements of brain blood flow in different parts of the brain?

- **Christian J. Pike, Ph.D.**
  University of Southern California
  Los Angeles, California
  *NeuroSARMS in the Prevention of Alzheimer’s Disease*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  Can selective androgen receptor modulators (SARMS) reduce the risk of Alzheimer’s disease in aging men?

- **Tiffany Mellott, Ph.D.**
  Boston University Medical Campus
  Boston, Massachusetts
  *Effect of Perinatal Choline Supplementation on an Alzheimer’s Disease Model*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Does choline help slow age-related memory declines?

- **Pavan Kumar Krishnamurthy, Ph.D.**
  Columbia University Medical Center
  New York, New York
  *Cellular Pathways for Antibody Mediated Removal of Tau Aggregates*
  2010 New Investigator Research Grant—$80,000 over 2 years
  Are tau antibodies effective at clearing different forms of tau?

- **Susan W. Liebman, Ph.D.**
  Ohio State University
  Columbus, Ohio
  *Evaluating Glial Glutamate Transporter EAAT2 Activators in APP Mice*
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  Can 10 potential drug candidates be identified and tested for their ability to inhibit beta-amyloid oligomerization?

- **Suzanne Craft, Ph.D.**
  Seattle Institute for Biomedical and Clinical Research
  Seattle, Washington
  *Intranasal Insulin Analogue Effects on CSF and Imaging Biomarkers in MCI*
  2010 Zenith Fellows Award—$449,966 over 2 years
  How does long-acting insulin affect cognitive function, brain blood flow and the levels of chemicals in the CSF known to be associated with MCI?
2. Nutritional and lifestyle interventions

• **David Morgan, Ph.D.**
  University of South Florida
  Tampa, Florida
  **Ketogenesis and Alzheimer Pathology**
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  How does the ketogenic state affect nerve cell death and brain function in mouse models that exhibit amyloid plaques and neurofibrillary tangles?

• **Kumar Sambamurti, Ph.D.**
  Medical University of South Carolina
  Charleston, South Carolina
  **Dietary Modification of Alzheimer Biomarkers**
  2010 Investigator-Initiated Research Grant—$200,000 over 3 years
  Do treatments that reduce homocysteine levels also reduce the development of Alzheimer-like pathology?

---

3. Care, support and social-behavioral factors

• **Yanira L. Cruz, M.P.H., D.Ph.**
  National Hispanic Council on Aging
  Washington, D.C.
  **Research Leading to Early Detection and Treatment of Alzheimer’s Disease Among Hispanics**
  2010 New Investigator Research Grant to Promote Diversity—$100,000 over 2 years
  What are the attitudes, level of stigma, level of knowledge and challenges for caregivers and healthcare providers related to Alzheimer’s disease in the U.S. Hispanic community?

• **Jesus Favela, Ph.D.**
  Center for Scientific Research and Higher Education of Ensenada
  Ensenada, Mexico
  **Offering Situational Awareness from Activity Estimation and Social Networks**
  2010 Everyday Technologies for Alzheimer Care Grant—$200,000 over 2 years
  Can a social networking system (SNS) enable people with Alzheimer’s disease and their caregivers to better manage daily activities and communication?

• **Brent E. Gibson, Ph.D.**
  The Jewish Home and Hospital for Aged
  New York, New York
  **Beliefs About Dementia-Related Symptoms Among African-Americans**
  2010 New Investigator Research Grant—$80,000 over 2 years
  How are dementia-related symptoms recognized, defined and assigned meaning (explanatory models) among African-Americans, and how can these explanatory models facilitate or inhibit help-seeking?
• **Laura N. Gitlin, Ph.D.**  
  Thomas Jefferson University  
  Philadelphia, Pennsylvania  
  *Managing Behavior in Nursing Homes: Innovative Intervention and Methods*  
  2010 Non-Pharmacological Strategies to Ameliorate Symptoms of Alzheimer's Disease—$320,000 over 2 years  
  Can the Tailored Activity Program for Nursing Homes (TAP-NH) effectively engage people with dementia in activities tailored to their abilities?

• **Maureen Schmitter-Edgecombe, Ph.D.**  
  Washington State University  
  Pullman, Washington  
  *A Multi-Dyad Cognitive Rehabilitation Intervention*  
  2010 Non-Pharmacological Strategies to Ameliorate Symptoms of Alzheimer's Disease—$320,000 over 3 years  
  Can a multifamily cognitive-rehabilitation intervention improve behavioral management skills in persons with MCI and supportive strategies by their care partners?